HEPP Report: Infectious Diseases in Corrections, Vol. 7 No. 6

HIV & Hepatitis Education Prison Project

Follow this and additional works at: http://digitalcommons.uri.edu/idcr

Recommended Citation
http://digitalcommons.uri.edu/idcr/57
The Hepatitis C virus (HCV) is a major public health problem and the most common cause of death from liver disease in the United States.1 According to population-based studies, HCV accounts for more than 40% of chronic liver disease in the U.S., and causes about 10,000 deaths per year.2 Although the proportion of these deaths that occur in correctional facilities is believed to be as high as 30% and rising, the exact numbers of deaths due to HCV that occur in the U.S. correctional system is unknown. Despite the declining incidence of HCV infection, the prevalence of HCV-related chronic liver disease is increasing because of a substantial time lag between infection and clinical manifestations.

Although the estimated prevalence of hepatitis C in the U.S. is about 2%,3 it is significantly higher in state and federal correctional facilities (16-49%).4-6 According to a U.S. Justice Department study, 1.3 to 1.4 million inmates released from prison in 1996 were infected with HCV, or about 30% of the total in the U.S. population with the condition.7 As in the general population, injection drug use (IDU) accounts for most HCV infections in the correctional setting, as up to two-thirds of inmates have a history of IDU before incarceration.8 Since there is such a high prevalence of HCV among inmates, the correctional environment affords an opportunity to diagnose and treat the virus in many of those who are HCV-infected.

The best therapy currently available for treatment-naïve patients is weekly injections of pegylated-interferon alpha-2a coupled with twice daily oral ribavirin. Sustained virologic response (SVR is defined as undetectable HCV RNA 24 weeks after the completion of therapy) can be achieved in more than half of those treated.9-10 However, early identification of treatment non-responders is warranted to spare the expense and side effects of unnecessary medication. Consequently, the use of the early virologic response (EVR) has been popularized.

The best marker of EVR in terms of sensitivity (capture the largest number of responders) and negative predictive value (eliminate the largest number of non-responders) is a decline in the HCV viral load of at least 2-log from baseline after 12 weeks of therapy. Patients not achieving this treatment milestone have...
almost no chance of achieving a SVR, and therefore can be spared an additional 12 to 36 weeks of unnecessary therapy. In a recently published economic analysis, the use of EVR decreased costs by 45% when compared to a full course of therapy. Based on these data, many experts recommend terminating therapy for patients who do not reach an EVR at 12 weeks.

There are several caveats to bear in mind when utilizing EVR. Because most patients with genotypes other than 1 achieve an EVR, using a 12-week cut-off reduces costs only marginally in patients with other genotypes. Secondly, variations of up to one 1 log unit can occur with any assay, so a patient with a 1.8-log RNA drop at 12 weeks, for example, may still achieve a sustained response. Moreover, histologic benefits may be achieved despite patients not reaching early or sustained virologic responses. Although many insurance companies have justified stopping coverage of medications for patients who do not reach this threshold, a patient may still show significant hepatic histologic improvement or at least delayed histologic progression without reaching an EVR/SVR. This topic will be discussed in greater detail below. Accordingly, use of EVR should be viewed as an individualized tool and not a hard and fast rule for terminating therapy.

Persistently Normal Aminotransferases (PNALT)

HCV is usually associated with elevated alanine aminotransferase (ALT) levels, yet about 30% of patients with chronic HCV have persistently normal ALT levels. The study of this patient subset has been compounded by differing definitions of a “normal” ALT. The definition of a normal ALT used in the phase III clinical trial of peginterferon alfa-2b and ribavirin was <43 IU/L for men and <34 IU/L for women. Patients with PNALT were defined as those with three separate blood tests drawn at least one month apart that demonstrated ALT measurement at or below the upper limit of the normal level. Although many patients with PNALT have a slow progression of fibrosis, some PNALT patients have relatively advanced fibrosis on liver biopsies. In a recent study of 91 HCV RNA-positive patients with PNALT (all of whom had liver biopsy), one in six patients had significant, progressive liver disease that was only identified on liver biopsy.

Treatment for the HCV patient with PNALT has been controversial. An older study of interferon monotherapy for those with PNALT showed that therapy caused elevations in ALT, and was therefore not beneficial. However, subsequent studies treating those with PNALT using standard interferon/ribavirin showed sustained response rates without ALT “flares” in 47% of the patients.

...some specialists believe that all PNALT patients who are otherwise candidates for treatment should undergo liver biopsy, and that treatment should be based on histology results.

The 2002 NIH Consensus Guidelines on the Management of HCV recommended that treatment for HCV patients with PNALT should be individualized, taking into account factors such as liver histology, HCV genotype, patient age, motivation for therapy and co-morbid conditions. A recently completed multicenter, multinational, randomized trial showed that HCV-infected PNALT patients had similar rates of sustained response compared to those with elevated ALTs when treated with pegylated-interferon/ribavirin.

In a recent study by Ghany, et al., 123 patients with chronic HCV underwent two liver biopsies, each at extended, but variable intervals. The biopsy reports were correlated with serum aminotransferases. The authors concluded that the best predictors of fibrosis progression in these patients were the extent of serum aminotransferase elevations and the degree of hepatocellular necrosis and inflammation on liver biopsy. Consequently, they felt these findings support the recommendation that patients with PNALT and mild liver histology can safely defer treatment. As a result of these studies and others, some specialists believe that all PNALT patients who are otherwise candidates for treatment should undergo liver biopsy, and that treatment should be based on histology results.

Liver Biopsy

The necessity of liver biopsy prior to treatment is also a subject of debate. Despite drawbacks like the potential for complications and sampling error, biopsy is the only reliable predictor of natural history of disease. Nearly all patients with high-grade necroinflammation and most of patients with intermediate-grade on biopsy develop cirrhosis. Nonetheless, the cost-effectiveness of treating patients without fibrosis on biopsy has been questioned. Expert consensus groups from the U.S. and Europe have previously recommended the routine performance of liver biopsy prior to antiviral therapy initiation. However, recent guidelines from the American Association for the Study of Liver Diseases (AASLD) are less dogmatic: “biopsy is not mandatory to initiate therapy…yet a liver biopsy should be done when results will influence the recommendation to treat”.

Different prison systems take different approaches to liver biopsy. The Federal Bureau of Prisons, Louisiana, and Georgia require a biopsy prior to treatment, and only treat those with significant fibrosis. On the other hand, Texas and Pennsylvania systems do not mandate biopsy for those who desire treatment and do not have contraindications. A recent cost-effectiveness study of HCV-infected inmates was carried out at the Louisiana State Penitentiary in which 501 patients were evaluated, approximately half of whom had pre-treatment liver biopsies. In an analysis of those patients infected with HCV genotype 1 who received pegylated-interferon/ribavirin, the cost of HCV treatment was $16,826 per patient treated with liver biopsy and $14,389 for those treated without liver biopsy. The authors concluded that a protocol using liver biopsy as a means to determine eligibility for therapy does in fact balance costs and complies with current recommendations.
Cirrhosis and Maintenance Therapy

Patients with HCV-related cirrhosis have a high risk of dying from end-stage liver disease (30% over 10 years), and thus have much to gain from successful treatment. Patients with advanced liver disease can be successfully treated with interferon-based therapies, but sustained response rates are lower and medication dose reductions are needed more frequently in this population relative to those with less advanced disease.

Most of the data supporting the treatment of compensated cirrhotics comes from subgroup analysis of larger trials in which 43% of those treated with pegylated-interferon/ribavirin achieve an SVR. Only one published treatment trial examined patients with advanced liver disease exclusively; cirrhotic patients on pegylated-interferon monotherapy achieved an SVR in 30% of cases. In patients who achieve SVR, the risk of developing hepatocellular carcinoma or liver failure may also be diminished.

Despite some data supporting the treatment of compensated cirrhotics, there is little evidence supporting therapy for those with decompensated liver disease (ascites, encephalopathy, etc.). These patients should be referred to liver transplantation centers or be enrolled in clinical trials. In patients who achieve SVR, the risk of developing hepatocellular carcinoma or liver failure may also be diminished.

Even if patients do not achieve an SVR, both cirrhotics and non-cirrhotics may still have significant hepatic histologic improvement or at least delayed histologic progression following treatment with combination therapy. In an analysis of data from over 3,000 patients receiving sequential liver biopsies, interferon-based treatment reduced the rate of fibrosis progression. Despite only a third of patients achieving SVR, nearly half had reversal of their cirrhosis. 73% of patients had improvement of necrosis and inflammation, irrespective of achieving SVR. In a more recent meta-analysis of over 1,000 treatment-naive patients, pegylated-interferon alfa-2a significantly reduced fibrosis relative to standard interferon.

Based upon the above two studies and others like them, some specialists support the concept of “maintenance therapy” in which patients with cirrhosis who do not achieve an SVR continue therapy in hopes of achieving a regression or slowing of their liver disease. Although many providers are utilizing maintenance therapy in their practices, this approach is still experimental since it has not been proven in well-controlled trials. Large multi-center trials such as HALT-C, COPILOT and EPIC are underway and will likely provide guidance on this issue.

“African-Americans with HCV-related cirrhosis may have up to a six times higher risk of developing hepatocellular carcinoma compared to their cirrhotic Caucasian counterparts.”

HCV and HIV Co-infection

HCV is common in HIV-infected patients because of shared routes of transmission. In fact, the U.S. Public Health Service and the Infectious Disease Society of America advocate screening all HIV-infected individuals for HCV. HIV seropositivity accelerates the rate of HCV-progression by about three-fold.

Many providers are treating co-infected patients for both diseases. The more intact the immune system (CD4+ count >200 cells/mm³), the higher likelihood of sustained response to HCV therapy. Several authors have recommended liver biopsy prior to initiating treatment for HCV in co-infected patients. Co-infected patients should be monitored closely because the concomitant use of nucleoside analogs and ribavirin increases the risk of pancreatitis, anemia and lactic acidosis. Furthermore, ribavirin is contraindicated with didanosine (ddi) since it increases risks of side effects associated with ddi. Finally, the potential for antiretroviral medication-induced hepatotoxicity is compounded in HCV-infected patients.

The results of recently completed trials of over 400 co-infected patients treated with pegylated-interferon alfa-2a/ribavirin have been made available. Sustained response rates ranged from 27 to 40%, yet discontinuation rates ranged from 12 to 25%. Both response rates and termination rates are significantly higher when compared to those from monoinfected HCV patients. However, in co-infected patients, the rates of SVR are better with treatment with pegylated-interferon alfa-2a than with treatment with standard non-pegylated interferon alpha-2a/ribavirin.

African-Americans and Hepatitis C

Compared with Caucasians, U.S. minority populations are disproportionately affected by chronic HCV infection. Furthermore, African-Americans are more likely to be infected with HCV genotype 1 and develop chronic infection than are Caucasians. Efforts to assess the natural history of HCV-infected African-Americans have been hampered by inadequate representation of African-Americans in HCV prospective trials. A retrospective study of over 350 patients showed that African-Americans had significantly less necrosis and cirrhosis on liver biopsy compared to Caucasians. Nonetheless, African-Americans with HCV-related cirrhosis may have up to a six times higher risk of developing hepatocellular carcinoma compared to their cirrhotic Caucasian counterparts.

With respect to interferon-based therapy, most studies have reported lower response rates among African-Americans compared to Caucasians. Ongoing studies of standard interferon/ribavirin combination therapy have shown lower sustained responses in African-Americans compared to Caucasians. The lower response rate may be due, in part, to an impaired ability of African-Americans to inhibit viral production and clear virus with therapy, but the reason for the discrepant response rates are still unclear.

Preliminary results are available from the first well-controlled clinical trial conducted exclusively in African-Americans infected...
Hot Topics in Hepatitis C...
(continued from page 3)

with genotype 1. This trial evaluated the safety and efficacy of pegylated-interferon alpha-2a/ribavirin treatment. When compared to the historical control group (genotype 1 patients of similar weight to those in the study), there was a lower rate of SVR, 26% versus 39%, respectively, for the trial participants and controls. The utility of EVR was confirmed in this population; i.e. EVR had a good negative predictive value in both studies involving African-Americans and non-African-Americans. Although no unexpected adverse effects were noted in this trial, African-Americans in this trial developed more neutropenia than did controls.\textsuperscript{59} For unknown reasons, the significance of neutropenia-related treatment was less clinically significant than previously thought, especially in African-Americans.\textsuperscript{60} Finally, the study showed that even the patients without an SVR achieved a benefit with respect to hepatic histology.\textsuperscript{61} In summary, although the likelihood of an SVR is decreased among African-Americans, are less than those of non-African-Americans, HCV treatment may be beneficial, and ethnicity should not be a criterion on which to base suitability of therapy.

Since there is such a high prevalence of HCV among inmates, the correctional environment affords an opportunity to diagnose and treat the virus in many of those who are infected. In this month’s Spotlight (David Thomas, J.D., MD) discusses the complex medical, legal, and financial issues surrounding HCV treatment in prisons and jails. The absence of any formal guidelines for treatment of HCV in correctional settings remains the most significant roadblock to providing good care to all HCV-infected inmates. The time is ripe for either the Society for Correctional Physicians or the National Commission on Correctional Health Care to develop these much-needed benchmark standards.

Disclosures:
*Brian Pearlman: Speakers’ Bureau: Schering-Plough
**Joe Paris: Nothing to disclose.

References:
24. Silverman AL, et al. 52nd AASLD; Nov 9-13, 2001; Dallas, TX.
34. EASL. J Hepatol. 1999;30:956-61.
41. USPHS and IDSA. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.
**Letter from the Editor**

Dear Correctional Colleagues:

An estimated two million Americans are infected with hepatitis C, which now accounts for more than 40% of chronic liver disease in the U.S. and causes about 10,000 deaths per year. In jails and prisons, the prevalence of HCV is ten to twenty times higher than that in the free population, and an estimated one-third of all HCV-infected Americans have spent time in jail or prison. By all measures, correctional health care systems are bearing the brunt of the responsibility for responding to this nation’s HCV epidemic. The financial aspects of this responsibility are overwhelming. Many correctional departments are faced with difficult decisions concerning allocation of inadequate resources.

Essential components of a comprehensive response to HCV should include:
- Education of at-risk persons about the importance of knowing their HCV serostatus
- Harm reduction education of at-risk individuals on how to prevent transmission of the virus
- Vaccination of hepatitis A and B non-immune individuals to protect them from further liver injury
- Alcohol and substance abuse treatment for those in need
- Treatment of those HCV-infected persons who are most likely to benefit

Some correctional health care programs have attempted to implement targeted HCV testing based upon risk assessment histories. As this month’s HIV 101 demonstrates, virtually all inmates fall into a risk group for which HCV testing would be recommended (individuals with abnormal alanine aminotransferase levels, those who have had more than 10 lifetime sex partners, those who have had a history of a sexually transmitted disease, injection-drug users, and men who have had sex with men.) Therefore, rather than attempting to coordinate risk-based screening, it is likely to be more cost-effective to simply offer testing for HAV, HBV, and HCV to all individuals whose serostatus is unknown.

This month, Drs. Brian L. Pearlman and Joseph E. Paris provide a review of current HCV issues including early viral response, management of those with persistently normal transaminases, the role of the liver biopsy, management of HIV co-infected persons, and treatment outcomes based upon racial background. In this month’s spotlight, Dr. David Thomas reviews HCV treatment from public health, legal, ethical, risk/benefit, and patient responsibility perspectives.

In an effort to reflect the broad spectrum of infectious diseases that impact the correctional setting, HEPP Report will soon be changing its name to IDCR: Infectious Diseases in Corrections Report. The print and online versions will continue to provide the same up-to-date information but in a more reader- and user-friendly format. We encourage our readers to share their opinions on both the content and new appearance of the newsletter.

Sincerely,

Joe Bick, MD

---

**Subscribe to HEPP Report**

Fax to **617-770-3339** for any of the following: *(please print clearly or type)*

____ Yes, I would like to add/update/correct (circle one) my contact information for my complimentary subscription of HEPP Report fax/email newsletter.

____ Yes, I would like to sign up the following colleague to receive a complimentary subscription of HEPP Report fax/email newsletter.

____ Yes, I would like my HEPP Report to be delivered in the future as an attached PDF file in an email (rather than have a fax).

NAME: ______________________ FACILITY: ______________________

CHECK ONE:

- Physician
- Physician Assistant
- Pharmacist
- Medical Director/Administrator
- Nurse/Nurse Practitioner
- Nurse Administrator
- HIV Case Worker/Counselor
- Other

ADDRESS: ______________________ CITY: ______________________ STATE: ____ ZIP: ________

FAX: ______________________ PHONE: ______________________

EMAIL: ______________________
The difficult question of if and when to treat those infected with Hepatitis C Virus (HCV) can be evaluated from a myriad of perspectives, including public health concerns, risk/benefit in corrections, legal issues, ethical issues, and personal physician-patient responsibility. The discussion that follows reflects the opinions of the author.

PUBLIC HEALTH CONCERNS
1. There is no clinical test for HCV disease risk to determine which of the 2.5 to 4 million HCV-infected people in the U.S. will develop liver failure or hepatocellular carcinoma, and therefore, are most in need of treatment.
2. Some of those who are infected may continue to participate in activities that put them at high risk for reinfection.
3. Most individuals (80%) do not develop complications from HCV infection.
4. HCV mutates easily, making it unlikely that a vaccine will be developed in the near future.

Reflecting these concerns, public health resources have been directed to the prevention of infection and disease. The goals of the National Hepatitis C Prevention Strategy are “to lower the incidence of acute hepatitis C in the United States and reduce the disease burden from chronic HCV infection,” through:
1. Harm reduction programs directed at persons at increased risk for infection to reduce the incidence of new HCV infections;
2. Counseling, testing, and medical evaluation and management of infected persons to control HCV-related chronic liver disease;
3. Surveillance to evaluate the effectiveness of prevention activities;
4. Research aimed at prevention and control of HCV.1

RISK/BENEFIT TO CORRECTIONAL HEALTHCARE SYSTEMS
Up to one third of those with HCV in this country have been incarcerated. Correctional health care workers see two discrete HCV epidemics in prisons and jails—one that is decades old and the other that is comprised of “rapid progressors, i.e. patients who are required to show problems with this disease.”2 HIV has a clear role in the more rapid progression of HCV disease in co-infected patients. In some prison systems, HCV has become the single largest cause of death,3 reminiscent of the situation of HIV a decade ago.

Although prisoners have a constitutional right to healthcare, correctional healthcare standards vary significantly from state to state. Some argue that to treat HCV aggressively would draw scarce resources away from other essential correctional healthcare programs. Prison budgets are at the whim of the respective state legislatures (and the U.S. Congress in the federal system), and must compete with all other healthcare initiatives. Few states have appropriated recurring funding for HCV care as they have for the treatment of HIV. Some prison systems have chosen to ignore the issue because with an average length of stay of less than three years,4 it is unlikely that while incarcerated, a patient with HCV will develop sequelae that will lead to an economic burden for the penal system.

However, some large systems, particularly in the South, have average lengths of stays that approach a decade.5 These systems are more likely to face the economic consequences of therapu-
The following table is adapted from the Centers for Disease Control and Prevention’s HCV web-based training course *Hepatitis C: What Clinicians and Other Health Professionals Need to Know*. The text is based upon the Recommendations for Prevention and Control of Hepatitis C Virus (HCV) Infection and HCV-related Chronic Disease*.

**Centers for Disease Control and Prevention. MMWR 1998; 47 (No. RR-19)**

**TABLE 1.** Estimated average prevalence of hepatitis C virus (HCV) infection in the United States by various characteristics and estimated prevalence of persons with these characteristics in the population.

<table>
<thead>
<tr>
<th>HCV-infection prevalence</th>
<th>Prevalence of persons with characteristic, %</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>% (range, %)</td>
</tr>
<tr>
<td>Persons with hemophilia treated with products made before 1987</td>
<td>87 (74-90) &lt;0.01</td>
</tr>
<tr>
<td>Injecting drug users</td>
<td></td>
</tr>
<tr>
<td>current history of prior use</td>
<td>79 (72-86) 0.5</td>
</tr>
<tr>
<td>Persons with abnormal alanine aminotransferase levels</td>
<td>15 (10-18) 5</td>
</tr>
<tr>
<td>Chronic hemodialysis patients</td>
<td>10 (0-64) 0.1</td>
</tr>
<tr>
<td>Persons with multiple sex partners (lifetime)</td>
<td></td>
</tr>
<tr>
<td>&gt;50</td>
<td>9 (6-16) 4</td>
</tr>
<tr>
<td>10-49</td>
<td>3 (3-4) 22</td>
</tr>
<tr>
<td>2-9</td>
<td>2 (1-2) 52</td>
</tr>
<tr>
<td>Persons reporting a history of sexually transmitted diseases</td>
<td>6 (1-10) 17</td>
</tr>
<tr>
<td>Persons receiving blood transfusions before 1990</td>
<td>6 (5-9) 6</td>
</tr>
<tr>
<td>Infants born to infected mothers</td>
<td>5 (0-25) 0.1</td>
</tr>
<tr>
<td>Men who have sex with men</td>
<td>4 (2-18) 5</td>
</tr>
<tr>
<td>General population</td>
<td>1.8 (1.5-2.3) NA*</td>
</tr>
<tr>
<td>Healthcare workers</td>
<td>1 (1-2) 9</td>
</tr>
<tr>
<td>Pregnant women</td>
<td>1 - 1.5</td>
</tr>
<tr>
<td>Military personnel</td>
<td>0.3 (0.2-0.4) 0.5</td>
</tr>
<tr>
<td>Volunteer blood donors</td>
<td>0.16 - 5</td>
</tr>
</tbody>
</table>

*Not applicable

**Spotlight…(continued from page 6)**

As with most ethical dilemmas, all sides have compelling arguments. In addition, most issues fall into grey areas.

**Personal Physician/Patient Responsibility**

Irrespective of our practice setting, each of us has a responsibility to our individual patients. This responsibility exceeds that of “what is good for most of the population.” This unique relationship is one reason why physicians understand the global problem of antibiotic overuse, but continue to excessively prescribe in their own practices. The legal issues notwithstanding, (which in the correctional setting include malpractice and licensure actions, as well as allegations of deliberate indifference and Civil Rights infractions) there is the matter of patient trust. Your patient expects you to do what is best for him or her. Your final decision is based on your background of knowledge, your ethical framework and the interaction between you and your patient at that particular moment in time.

This kind of subjectivity is the nemesis of managed care companies. As physicians, we claim it is part of the art of medicine. It is one of the major reasons there is not uniformity of decision-making among physicians or, more importantly, even for a single physician seeing patients with similar problems. Most of us would comfortably say medicine is an art as well as a science and explain it that way. Should it not be our unique physician/patient relationship that determines whether to treat or not to treat? After all, it is our name on the prescription and our irrevocable, non-delegable responsibility for the patient.

**Disclosures:**

*Nothing to disclose.

**References:**

5. Ibid.
### Save the Dates

**National HIV Testing Day (NHTD)**  
*June 27, 2004*  
**Nationwide**  
Call: (202) 464-5652  
Email: pfeldman@napwa.org  
Visit: www.nhtd.org

**2004 Annual Conference on Antimicrobial Resistance**  
*June 28 - 30, 2004*  
**Bethesda, MD**  
Call: (301) 656 0003 x19  
Fax: (301) 907 0878  
Email: scooper-kerr@nfid.org  
Visit: www.nfid.org/conferences/preregistration/2004/

**XV International AIDS Conference**  
*July 11 - 16, 2004*  
**Bangkok, Thailand**  
Visit: www.aids2004.org/

**Centerforce 5th Annual Inside/Out Summit**  
*September 11-15, 2004*  
**Burlingame, CA**  
Contact: Beth Houghton  
Call: 415-456-9980 x124  
Visit: www.centerforce.org/

**Infectious Disease Society of America**  
*September 30 - October 3, 2004*  
**Boston, MA**  
Early preregistration deadline is July 7. Regular Registration Deadline is August 26.  
Visit: www.idsociety.org

**44th Annual ICAAC**  
*October 30 - November 2, 2004*  
**Washington, DC**  
Discounted preregistration deadline is August 27. Final Preregistration deadline is September 24.  
Visit: www.asm.org

**National Conference on Correctional Health Care**  
*November 13 - 17, 2004*  
**New Orleans, LA**  
Tel: 773.880.1460  
Visit: www.archel.org

---

### INSIDE NEWS

**FDA Approves Viracept® 625 mg Tablets**  
The Food and Drug Administration recently approved a new alternate dosing formulation of Viracept® (nelfinavir mesylate). The new formulation of 625 mg reduces the pill burden from five 250 mg tablets bid to two 625 mg tablets bid, potentially facilitating adherence to treatment regimens. It is recommended that Viracept® be taken with a meal. Both retail and correctional pharmacies will have the product in stock as of June 1, 2004.  
Visit: www.viracept.com

**National HCV/HIV Coinfection Coalition Meets Capitol Hill**  
*AIDS Report* was among the several HCV/HIV coinfection advocacy groups represented at the National HIV/Hepatitis C Coinfection Coalition’s first round of visits to key House and Senate members on April 6 and 7, 2004. At the core of the Coalition’s message was increased funding for programs that address the specific needs of coinfected individuals. Incorporating specific language on HCV/HIV coinfection into the Ryan White Care Act (RWCA) was identified by the Coalition as the most effective vehicle for attaining this goal. The Coalition also advocated for available funding for testing, the implementation of an effective referral system for coinfected patients, and increased funding for ADAPs (AIDS Drug Assistance Programs) so they can incorporate drugs to treat coinfected into their formularies. It is estimated that 30% of the 900,000 HIV-infected individuals are coinfected with HCV, and this percentage is projected to be higher among those who access ADAP funding. Furthermore, it is estimated that 60-90% of those who acquired HIV through intravenous drug use are also HCV-infected. While ADAP does not cover incarcerated patients, the outcome of this issue will certainly have serious implications for the thousands of coinfected inmates released each year. While individual members of Congress supported the Coalition’s arguments, the question of finding the money was a recurring issue for some. The outcome of the Coalition’s efforts will be decided when RWCA comes up for reauthorization by the U.S. Congress later this year, marking the third round of negotiations for reauthorization of the government’s landmark legislation dealing specifically with HIV/AIDS care.  
Julia Noguchi, Managing Editor, HEPP Report

**HAART with PI Less Likely to Show Liver Fibrosis**  
In a cross-sectional Spanish study of HIV/HCV coinfected patients from a cohort of HIV-infected patients, authors found that the use of HAART regimens including nevirapine is associated with an increased degree of liver fibrosis in HIV-infected patients with chronic HCV. Toxicity related to nevirapine can include either an early idiosyncratic reaction or a late-onset cumulative toxicity, both of which might be implicated in the worsening liver fibrosis among HIV-infected patients with chronic HCV. Patients receiving a protease inhibitor (PI) were less likely to show liver fibrosis. The results of this study suggest that HAART including a PI may be more advantageous in terms liver fibrosis progression than nevirapine-based regimens in HCV co-infected persons. The associations found in this study have not been confirmed by randomized prospective studies with hard clinical end-points, such as development of decompensated cirrhosis or death attributable to liver failure.  

**Undetectable HIVViral Load Slows Liver Disease Progression in HCV-HIV Co-infection**  
As reported at the European Association for the Study of the Liver Conference (EASL) - Berlin, Germany, April 14-18, 2004, HCV-HIV co-infected patients with suppressed HIV RNA (<400 copies/ml) have a similar rate of fibrosis as HIV-negative patients with HCV. Co-infected patients with uncontrolled HIV viremia have more rapid fibrosis rates than both patients with suppressed HIV RNA and those who are HIV-negative. In co-infection, the rate of fibrosis is independently predicted by log HIV viral load, Ishak necro-inflammatory score, and age at HCV infection; and not by CD4 cell count or alcohol use. Study authors suggest that in co-infected persons, consideration should be given to starting HAART earlier (when CD4 cells are <500) to slow HCV-related fibrosis.  
NATAP - www.natap.org

---

### Resources

**The CDC’s Advisory Committee on Immunization Practices (ACIP) revised guidelines for the Prevention and Control of Influenza:**  
www.cdc.gov/mmwr/preview/mmwrhtml/rr53e430a1.htm

**HIV and Hepatitis PDF reports formatted for print:**  
www.hivandhepatitis.com/reports/2003list.html

**National Institutes of Health Consensus Development Conference Statement - Management of Hepatitis C:**  
June 10-12, 2002:  

**National Center for Infectious Diseases, Viral Hepatitis C**  
www.cdc.gov/nccdod/diseases/hepatitis/c/plan/implementation.htm
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through December 31, 2004. The estimated time for completion of this activity is one hour and there is no fee for participation.

1. The percentage of chronic liver disease in the U.S. that can be attributed to hepatitis C virus (HCV) is approximately:
   a) 20
   b) 40
   c) 60
   d) 80

2. Sustained virologic response (SVR) is defined as:
   a) undetectable HCV RNA 24 weeks after completion of therapy
   b) undetectable HCV RNA 12 weeks after completion of therapy
   c) a decline in the HCV viral load of at least 2 log from baseline after 12 of therapy
   d) a decline in the HCV viral load of at least 2 log from baseline after 24 of therapy

3. Which statement best supports the argument that an early viral response (EVR) should be used as an individualized tool rather than a hard and fast rule for terminating therapy:
   a) A recent economic study has shown that the use of EVR decreased costs by 45%.
   b) Patients not achieving an EVR have almost no chance of achieving an SVR.
   c) Some patients may obtain histologic benefit from HCV therapy even if they do not reach early or sustained virologic responses.
   d) None of the above

4. Which of the following statements is supported by the literature:
   a) Among those who are HIV-infected, the rate of progression of HCV-related fibrosis is slowed.
   b) As compared to those who are not infected with HCV, HIV-infected persons who are also HCV-infected experience a markedly increased rate of decline of CD4 cells.
   c) Among those who are HIV-infected, the rate of progression of HCV related fibrosis is accelerated.
   d) Among those who are HCV-infected, co-infection with HIV markedly decreases the likelihood of achieving an EVR and a SVR.

5. The ethnic group that has the highest rate of HCV genotype 1 infection is:
   a) Hispanics
   b) Caucasians
   c) Asian/Pacific Islanders
   d) African-Americans

6. Policies and procedures for HCV care and treatment in the correctional setting varies significantly from state to state. True or False.
   a) True
   b) False

---

HEPP REPORT EVALUATION

5 Excellent 4 Very Good 3 Fair 2 Poor 1 Very Poor

1. Please evaluate the following sections with respect to:
   educational value clarity
   Main Article 5 4 3 2 1  5 4 3 2 1
   Inside News 5 4 3 2 1  5 4 3 2 1
   Save the Dates 5 4 3 2 1  5 4 3 2 1

2. Do you feel that HEPP Report helps you in your work? Why or why not?

3. What future topics should HEPP Report address?

4. How can HEPP Report be made more useful to you?

5. Do you have specific comments on this issue?

---

BROWN MEDICAL SCHOOL • OFFICE OF CONTINUING MEDICAL EDUCATION • BOX G-A2 • PROVIDENCE, RI 02912

The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

The use of the Brown Medical School name implies review of the educational format and material only. The opinions, recommendations and editorial positions expressed by those whose input is included in this bulletin are their own. They do not represent or speak for the Brown Medical School.

For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.

Name ___________________________________________________________ Degree ____________________

Address _______________________________________________________________________________________________________

City _______________________________ State ________ Zip __________________

Telephone ___________________________ Fax ___________________________________________